RxDoctor Payments Data

Vincent Lam, MD

Ophthalmology · Philadelphia, PANPI 1477713576

Payments from drug & device makers

$2,211in general payments, 2019–2025

Across 36 payments — averaging $61.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alcon$522
  • Sight Sciences, Inc.$246
  • Oyster Point Pharma, Inc.$143
  • Bausch & Lomb Americas Inc.$48
  • Sun Pharmaceutical Industries Inc.$40
  • plus $135 from 6 others

What the payments were for

  • Consulting fees$1,00045%
  • Food & beverage$1,15552%
  • Gifts$563%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,211 in reported general payments places this provider in the 60th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$148,390
Medicare patients
409
Services billed
1,514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine1,336$881,489
XiidraLifitegrast420$292,008
Cyclosporine478$121,654
TyrvayaVarenicline Tartrate106$68,343
LumiganBimatoprost204$51,280
MieboPerfluorohexyloctane/Pf41$31,117
Prednisolone Acetate503$15,063
Alphagan PBrimonidine Tartrate65$11,972
Latanoprost1,275$10,999
BotoxOnabotulinumtoxina16$10,486
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol67$8,556
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat406$8,510
Brimonidine Tartrate396$7,190
RocklatanNetarsudil Mesylat/Latanoprost19$6,305
Travoprost50$4,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Botox, Combigan$1,078$959,7671,646 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$48$326,250474 claims
Oyster Point Pharma, Inc.Tyrvaya$143$68,343106 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$14$10,08631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →